Open an account

X4 Pharmaceuticals

XFOR · NASDAQ

$3.02+$0.27 (+9.82%)TodayMarket closed ·
Prev close $2.75

About XFOR

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The company is headquartered in Boston, Massachusetts and currently employs 45 full-time employees. The company went IPO on 2017-11-16. The firm is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. The company has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). The company has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Employees
45
Headquarters
Boston, Massachusetts
Listed
Nov 16, 2017
Sector
Health Care
Industry
Biotechnology
Website
x4pharma.com

XFOR key statistics

Market cap
377.28M
Price-earnings ratio
137.50
Dividend yield
—
Average volume
910.91K
Volume
593.34K
Open price
$2.79
High today
$3.07
Low today
$2.77
52 Week high
$4.83
52 Week low
$2.43

X4 Pharmaceuticals (XFOR) at a glance

X4 Pharmaceuticals (XFOR) last traded at $3.02, with a market cap of 377.28M and a price-to-earnings ratio of 137.50.

Today the stock has traded between $2.77 and $3.07. The current price is 9.0% above the day's low and 1.6% below its high.

Volume so far is 593.34K shares, below the average of 910.91K shares a day.

Over the past year X4 Pharmaceuticals has ranged from $2.43 to $4.83, and now sits 25% of the way up that range.

X4 Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.13 per share against an estimate of -$0.1836.

The average analyst price target is $11.83, 291.8% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $11.83
Low
$10.10
Now
$3.02
High
$13.65

XFOR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 39.6% on average.

  1. Q3 FY24: reported -$5.40 per share against an estimate of -$5.29
  2. Q4 FY24: reported -$6.00 per share against an estimate of -$5.36
  3. Q1 FY25: reported $0.04 per share against an estimate of -$4.53
  4. Q2 FY25: reported -$3.47 per share against an estimate of -$4.42
  5. Q3 FY25: reported -$0.69 per share against an estimate of -$0.9343
  6. Q4 FY25: reported -$0.22 per share against an estimate of -$0.3545
  7. Q1 FY26: reported -$0.16 per share against an estimate of -$0.204
  8. Q2 FY26: reported -$0.13 per share against an estimate of -$0.1836

XFOR news

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releaseGlobe Newswire

    X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

  • Breaking Down X4 Pharmaceuticals: 4 Analysts Share Their Views

  • Press releaseGlobe Newswire

    X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Similar companies

Companies in the same industry as X4 Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.